

ATC codes: J05AR03

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: <a href="#">1C62.Z</a>
INN	Emtricitabine + tenofovir
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
EML status history	First added in 2007 ( <a href="#">TRS 946</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	lamivudine + tenofovir (ATC codes: J05AR12)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more about patents. 
Wikipedia	<a href="#">Emtricitabine + tenofovir</a> 
DrugBank	<a href="#">Emtricitabine</a>  , <a href="#">Tenofovir (Tenofovir disoproxil)</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for emtricitabine + tenofovir on the EML.

